Skip to content

Hematoma Block for Reduction of Distal Radius Fractures

Phase 4 Study of Hematoma Block for Reduction of Distal Radius Fractures

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02129270
Enrollment
24
Registered
2014-05-02
Start date
2014-05-31
Completion date
2018-08-31
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fractures of the Distal Radius

Keywords

Fractures of the distal radius, Hematoma block, Lidocaine

Brief summary

The purpose of this study is to Prove that injection of 15 to 20 mL of lidocaine 1% into the fracture site (Hematoma block) is more effective in terms of pain relieving then injection of 10 mL of lidocaine 2%, and equally safe in terms of complications, for closed reduction of distal radius fractures.

Interventions

DRUGLidocaine HCl 2% .

comparison of different dosages of drug

comparison of different dosages of drug

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Fractures of the distal radius, with or without ulna fracture

Exclusion criteria

* Children, * pregnant women, * patients with infection or suspected infection on the site for injection. * Patients whose condition requires general anesthesia (patients with more fractures other than the distal radius and ulna, patients with many damage...)

Design outcomes

Primary

MeasureTime frame
This study will be measured effective in terms of pain relieving with Visual Analog Scale.1 year

Secondary

MeasureTime frameDescription
This study will be measured safe in terms of complications to injection.1 yearNumber of Participants with Adverse Events as a Measure of Safety and Tolerability.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026